Share Name Share Symbol Market Type Share ISIN Share Description
Faron Pharmaceuticals Oy LSE:FARN London Ordinary Share FI4000153309 ORD NPV (DI)
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 340.00 18,630 08:00:13
Bid Price Offer Price High Price Low Price Open Price
330.00 350.00 340.00 330.75 340.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -15.09 -32.97 181
Last Trade Time Trade Type Trade Size Trade Price Currency
09:54:59 O 12,500 334.00 GBX

Faron Pharmaceuticals Oy (FARN) Latest News

More Faron Pharmaceuticals Oy News
Faron Pharmaceuticals Oy Investors    Faron Pharmaceuticals Oy Takeover Rumours

Faron Pharmaceuticals Oy (FARN) Discussions and Chat

Faron Pharmaceuticals Oy Forums and Chat

Date Time Title Posts
23/9/202111:44Respite for ARDS sufferers1,580

Add a New Thread

Faron Pharmaceuticals Oy (FARN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Faron Pharmaceuticals Oy trades in real-time

Faron Pharmaceuticals Oy (FARN) Top Chat Posts

Faron Pharmaceuticals Oy Daily Update: Faron Pharmaceuticals Oy is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker FARN. The last closing price for Faron Pharmaceuticals Oy was 340p.
Faron Pharmaceuticals Oy has a 4 week average price of 328.25p and a 12 week average price of 328.25p.
The 1 year high share price is 495p while the 1 year low share price is currently 220p.
There are currently 53,232,032 shares in issue and the average daily traded volume is 12,764 shares. The market capitalisation of Faron Pharmaceuticals Oy is £180,988,908.80.
sharesoc: The presentation packs and recording from our webinar with Faron Pharma on 3rd Nov can be found here for full members to view: hTTps://www.sharesoc.org/seminar/sharesoc-webinar-with-faron-pharmaceuticals-farn-3-november-2020/ To access the presentation, you'll need to be a full member of ShareSoc, which is a not-for-profit organisation that supports individual shareholders and campaigns for shareholder rights. If you're not already a member you can join here: hxxps://www.sharesoc.org/membership/ Once you've joined, you'll receive an invitation to register for our "members network" private social network, from where you'll be able to access the presentation (and presentations on 100s of other meetings). If you're already a member and have any difficulty accessing the report, please do not hesitate to contact us here: hxxps://www.sharesoc.org/contact-us/
sharesoc: Potential investors and current shareholders may be interested in our webinar with Faron Pharmaceuticals (FARN), 3 November 2020 hTTps://www.sharesoc.org/events/sharesoc-webinar-with-faron-pharmaceuticals-farn-3-november-2020/
toffeeman: This is Farn IV I think “ Solidarity’s “most disappointing results,” however, are those for interferon-beta, says Topol. Mortality among the 2050 people who received that drug (either alone or in combination with lopinavir/ritonavir) was 11.9%, versus 10.5% in the control group". htTps://www.sciencemag.org/news/2020/10/remdesivir-and-interferon-fall-flat-who-s-megastudy-covid-19-treatments
raldo: Interesting price action today - volume picking up a bit
ih_752952: DNL =3x Approvals expected during next 2 months including an Orphan Drug with FDA decision on September 29 = CHEAPEST UK Biotech a potential 500%++ GEM Diurnal Group (DNL) = MCap £38 M / Cash £15 M or enough untill early 2022 / LOTS of BIG milestones on the way = Still the MOST attractive and CHEAPEST pharma stock in UK has potential to run toward 200p very fast especially on approval of Alkindi in USA (expected in September) and Chronocort in Europe (expected in Q1 ) =STRONG BUY AGGRESSIVE a sleeping giant here .GL Market Cap £38 million Cash £15 million Price 30p Alkindi approval in Australia expected this Quarter Alkindi approval in Israel expected this Quarter FDA decision for Alkindi on September 29 EMA Decision for Chronocort expected in early Q1 2021
diversification: They did say that, but was that an opinion or stated fact backed up with trial results? I'm not looking to argue with you, I also managed to financially benefit from the rise in SNG, but the conference call was less than impressive imo. Good luck with your investment, I assume you also hold FARN to be positing here?
timberwolf3: Strange that it's so quiet here considering what they potentially have, i assume it will not be long before FARN is in the spotlight.
toffeeman: hash - it's completely different FARN is an injectible SNG is nebulised (I hold both)
bwgs: Thank you for your reply.To date I have to say I'm very encouraged as an investor in the way Farn is moving.In respect of 3rd party funding, it may well be that Farn are being very cautious, and not willing to dilute to high heaven (which is what usually happens on AIM).Would be great to see this going back to £8+
bioking: DNL about to explode , Institutional investor added 1 million shares this week . LOTS of BIG NEWS around the corner =10+ BAGGER GEM RALLLYYYYYYYYYYYY Diurnal (DNL) Market Cap £27 M Price: 31p Upcoming Catalysts: MAA-Acceptance for Chronocort in February/March 2020 Alkindi approval in Israel expected in 2Q 2020 Alkindi approval in Australien expected in 2Q 2020 US-Partnership for Alkindi & Chronocort expected in 1H 2020 Alkindi & Chronocort Partnership for Asia für Japan und China US-Approval for Alkindi expected in 4Q 2020 EU Approval for Chronocort expected in 4Q/1Q 2020/21 Investment summary:Alkindi, a cortisol replacement therapy designed for children under 18 years of age, is DNL’s first product on the market. It is expected to be followed by Chronocort for adults – a larger market – which now has a clear pathway for regulatory approval in both Europe and the US. Despite this, the share price is still languishing well below valuations determined by peer group and DCF (202p) analyses
Faron Pharmaceuticals Oy share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Faron Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211018 22:18:43